This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delbue, S.
Right arrow Articles by Ferrante, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delbue, S.
Right arrow Articles by Ferrante, P.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2008, p. 2461-2462, Vol. 46, No. 7
0095-1137/08/$08.00+0     doi:10.1128/JCM.00381-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

FAST-TRACK COMMUNICATION

First Identification and Molecular Characterization of Lymphotropic Polyomavirus in Peripheral Blood from Patients with Leukoencephalopathies{triangledown}

Received 26 February 2008/ Returned for modification 7 March 2008/ Accepted 30 April 2008


arrow
INTRODUCTION
 
Lymphotropic polyomavirus (LPV) was first isolated in 1979 from a B-lymphoblastoid cell line of an African green monkey by zur Hausen and Gissman (10). This virus has some characteristics common to human polyomavirus, such as virion morphology, the presence of a closed circular double-stranded molecule of DNA, and in vitro transforming activity (7), but it is antigenically distinct from simian virus 40, BK virus, and JC virus (1). In cell cultures, LPV has a highly restricted host range for both human and monkey B lymphoblasts (2, 3), and seroepidemiological studies revealed that, in addition to sera from monkeys, many human sera had strong reactions in the presence of LPV antigens (8).

More recently, Lednicky and colleagues were able to detect a fragment of the LPV genome in the blood of an immunocompromised rhesus monkey (5), but neither LPV nor any other related virus has been isolated from human biological fluids or tissues.

In order to investigate the possible presence of LPV in human specimens, we examined DNA extracted from peripheral blood mononuclear cells (PBMCs) that were collected from Italian human immunodeficiency virus-positive (HIV+) patients who were affected with different forms of leukoencephalopathies or other neurological diseases (OND), as well as HIV+ subjects with no neurological disorders (NND). We also collected cells from healthy control (HC) subjects. All the individuals gave written consent for enrollment in the study.

In particular, the LPV genome was searched by means of nested PCR targeting the viral transcriptional control region (TCR) (5) in DNA from 10 patients with progressive multifocal leukoencephalopathy (PML), 10 with not determined JC virus-negative leukoencephalopathy (NDLE), 10 with OND, 10 with NND, and 10 HC subjects. Plasmid pLPV-K38, containing a full-length genome of strain LPV-K38 (6), was used as a positive-control template for the amplification assay.

The LPV control region was successfully amplified from three DNA extracts: one from PBMCs collected from a PML patient and two from PBMCs collected from two NDLE patients. However, the bands created by the inner PCR were different in size (520 bp and 270 bp). The amplified fragments, together with the positive control, were subjected to direct automated sequencing according to published procedures (4), and the obtained nucleotide sequences were aligned with the GenBank database. DNA isolation, PCR, and sequencing were repeated twice. Cross-referencing with the database showed the expected complete nucleotide identity (100%) of LPV (GenBank accession number K02562.1) to the LPV-K38 control, whereas lower nucleotide identities of the LPV genome to the amplified TCR from the PBMCs of the patients were shown.

In particular, the molecular organization of the LPV TCR amplified from the PML patient was rearranged, as well as the LPV-K38 control, but five nucleotide (nt) changes were detected between the two viral strains (nt 110, 222, 335, 394, and 408; numbering is relative to strain LPV-K38). Two archetypal LPV regulatory regions were identified in the PBMCs from the two NDLE patients. To rule out the hypothesis that a cross-contamination between the samples could have happened during the nested-PCR procedures, the two archetypal sequences were aligned and differences in six places were discovered between the two strains (nt 126, 129, 133, 201, 269, and 555; numbering is relative to strain LPV-K38). As shown in Fig. 1, the ori region and the enhancer 63-bp subgenomic element of the rearranged sequence found in the PML patient were duplicated in comparison to the archetypal sequence that was amplified from the two NDLE patients.


Figure 1
View larger version (46K):
[in this window]
[in a new window]

  		FIG. 1. Schematic representation of the amplified TCR sequences. (A) Comparison between the rearranged TCR form amplified from the PML patient (pm1) and the one amplified from the plasmid of LPV-K38. (B) Comparison between the two TCR archetypal forms amplified from the two NDLE patients. The LPV PCR primer binding sites are indicated by LPR1 and LPR2. The arrows indicate the point mutation positions. The T-antigen recognition pentanucleotides are boxed with a solid line, while the enhancer 63-bp subgenomic elements are boxed with a dashed line. The ori region is underlined with a solid line.

In order to confirm these findings, another PCR targeting the VP1 region was performed. Specific primers LPV1 (nt 1765 to 1784) and LPV2 (nt 1966 to 1985) were used, and a 221-bp VP1 fragment from the PML patient and one of the NDLE patients was successfully amplified. A lack of material prevented us from performing the PCR with the PBMCs from the third patient (data not shown).

Even if the investigated human population was limited, it is noteworthy that the LPV genome was found exclusively in the peripheral blood of patients with the two different forms of leukoencephalopathies but not in the OND, NND, or HC cases. Moreover, two different molecular organizations of the viral TCR were detected, and based on what is known about human polyomaviruses (9), we can hypothesize that the archetypal organization is probably the form naturally transmitted (5), whereas rearranged forms, derived from partial duplication of the archetypal nucleotide sequence, could be generated as a consequence of highly active viral replication.

To the best of our knowledge, this is the first direct detection of the LPV genome in human peripheral blood, and this validates current seroepidemiological evidence suggesting the presence of LPV-like infections in human subjects. Due to the small number of studied subjects, we cannot draw a clear conclusion, but the data suggest at least the possible involvement of LPV in central nervous system leukoencephalopathies occurring in HIV+ individuals.

The isolation of LPV and/or whole-genome sequencing of the virus will be necessary to additionally support the significance of our results; however, the presence of the viral DNA in human blood cells is an important finding and warrants further investigations that may correlate LPV infection with specific human diseases.


arrow
Nucleotide sequence accession numbers.
 
The GenBank accession numbers for the two archetypal sequences and the rearranged sequences determined in this study are EU559168, EU559169, and EU559170, respectively.


arrow
ACKNOWLEDGMENTS
 
This study was supported by NIMH grant no. MH072528.

We thank Michael Pawlita for the gift of plasmid LPV-K38.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 14 May 2008. Back


arrow
REFERENCES
 
    1
  1. Brade, L., N. Muller-Lantzsch, S. Kaiser, and M. Scharrer. 1983. Biochemical studies on structural and non-structural proteins of African green monkey B-lymphotropic papovavirus (LPV). Virology 127:469-474.[CrossRef][Medline]
    2. 2
  2. Brade, L., N. Muller-Lantzsch, and H. zur Hausen. 1981. B-lymphotropic papovavirus and possibility of infections in humans. J. Med. Virol. 6:301-308.[Medline]
    3. 3
  3. Brade, L., W. Vogl, L. Gissman, and H. zur Hausen. 1981. Propagation of B-lymphotropic papovavirus (LPV) in human B-lymphoma cells and characterization of its DNA. Virology 114:228-235.[CrossRef][Medline]
    4. 4
  4. Delbue, S., G. Sotgiu, D. Fumagalli, M. Valli, E. Borghi, R. Mancuso, E. Marchioni, R. Maserati, and P. Ferrante. 2005. A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum and urine. J. Neurovirol. 11:51-57.[CrossRef][Medline]
    5. 5
  5. Lednicky, J. A., S. J. Halvorson, and J. S. Butel. 2002. PCR detection and DNA sequence analysis of the regulatory region of lymphotropic papovavirus in peripheral blood mononuclear cells of an immunocompromised rhesus macaque. J. Clin. Microbiol. 40:1056-1059.[Abstract/Free Full Text]
    6. 6
  6. Pawlita, M., A. Clad, and H. zur Hausen. 1985. Complete DNA sequence of lymphotropic papovavirus: prototype of a new species of the polyomavirus genus. Virology 143:196-211.[CrossRef][Medline]
    7. 7
  7. Takemoto, K. K., and K. Tadahito. 1984. Lymphotropic papovavirus transformation of hamster embryo cells. J. Virol. 50:100-105.[Abstract/Free Full Text]
    8. 8
  8. Viscidi, R. P., and B. Clayman. 2006. Serological cross reactivity between polyomavirus capsids. Adv. Exp. Med. Biol. 577:73-84.[Medline]
    9. 9
  9. Yogo, Y., T. Kitamura, C. Sugimoto, T. Ueki, Y. Aso, K. Hara, and F. Taguchi. 1990. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J. Virol. 64:3139-3143.[Abstract/Free Full Text]
    10. 10
  10. zur Hausen, H., and L. Gissman. 1979. Lymphotropic papovavirus isolated from African green monkey and human cells. Med. Microbiol. Immunol. 167:137-153.[CrossRef][Medline]
Serena Delbue
Sara Tremolada
Emanuela Branchetti
Francesca Elia
Elisa Gualco
Laboratory of Molecular Virology
Department of Biomedical Sciences and Technologies
University of Milan
Milan, Italy

Enrico Marchioni
Neurology Department
Mondino Hospital, IRCCS
Pavia, Italy

Renato Maserati
Clinic of Infectious Diseases
Policlinico San Matteo, IRCS
Pavia, Italy

Pasquale Ferrante*
Center for Translational Research and Laboratory of Pathology
Saint Joseph Hospital, MilanoCuore
Milan, Italy

* Phone: 39 0285994877 Fax: 39 0285994849 E-mail: pasquale.ferrante{at}unimi.it Back

Journal of Clinical Microbiology, July 2008, p. 2461-2462, Vol. 46, No. 7
0095-1137/08/$08.00+0     doi:10.1128/JCM.00381-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Focosi, D., Kast, R. E., Maggi, F., Ceccherini-Nelli, L., Petrini, M. (2009). Lymphotropic Polyomavirus and Progressive Multifocal Leukoencephalopathy. J. Clin. Microbiol. 47: 284-284 [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delbue, S.
Right arrow Articles by Ferrante, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delbue, S.
Right arrow Articles by Ferrante, P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»